2026-08-23T19:36:39Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1017122025-03-18T12:43:46Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Martínez Cuadrón, David author Gil, Cristina author Serrano, Josefina author Rodríguez, Gabriela author Pérez Oteyza, Jaime author García Boyero, Raimundo author Jiménez Bravo, Santiago author Vives, Susana author Vidriales, María Belén author Lavilla, Esperanza author Pérez Simón, José A. author Tormo, Mar author Colorado, Mercedes author Bergua, Juan author López, Juan A. author Herrera, Pilar author Hernández Campo, Pilar author Gorrochategui, Julián author Primo, Daniel author Rojas, Jose Luis author Villoria, Jesús author Moscardó, Federico author Troconiz, Iñaki author Linares Gómez, María author Martínez López, Joaquín author Ballesteros, Joan author Sanz, Miguel author Montesinos, Pau author 2019-01 Complete remission (CR) after induction therapy is the first treatment goal in acute myeloid leukemia (AML) patients and has prognostic impact. Our purpose is to determine the correlation between the observed CR/CRi rate after idarubicin (IDA) and cytarabine (CYT) 3 + 7 induction and the leukemic chemosensitivity measured by an ex vivo test of drug activity. Bone marrow samples from adult patients with newly diagnosed AML were included in this study. Whole bone marrow samples were incubated for 48 h in well plates containing IDA, CYT, or their combination. Pharmacological response parameters were estimated using population pharmacodynamic models. Patients attaining a CR/CRi with up to two induction cycles of 3 + 7 were classified as responders and the remaining as resistant. A total of 123 patients fulfilled the inclusion criteria and were evaluable for correlation analyses. The strongest clinical predictors were the area under the curve of the concentration response curves of CYT and IDA. The overall accuracy achieved using MaxSpSe criteria to define positivity was 81%, predicting better responder (93%) than non-responder patients (60%). The ex vivo test provides better yet similar information than cytogenetics, but can be provided before treatment representing a valuable in-time addition. After validation in an external cohort, this novel ex vivo test could be useful to select AML patients for 3 + 7 regimen vs. alternative schedules. Martínez Cuadrón, D., Gil, C., Seerano, J. et al. «A Precision Medicine Test Predicts Clinical Response after Idarubicin and Cytarabine Induction Therapy in AML Patients». Leukemia Research, vol. 76, enero de 2019, pp. 1-10. DOI.org (Crossref), https://doi.org/10.1016/j.leukres.2018.11.006. 0145-2126 10.1016/j.leukres.2018.11.006 https://hdl.handle.net/20.500.14352/101712 https://doi.org/10.1016/j.leukres.2018.11.006 A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients